CD20 (membrane-spanning 4-domains, subfamily A, member 1)
Target has curated data in GtoImmuPdb
Target id: 2628
Nomenclature: CD20 (membrane-spanning 4-domains, subfamily A, member 1)
Family: CD molecules
Annotation status:
Awaiting annotation/under development. Please contact us if you can help with annotation.
» Email us
Contents:
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 4 | 297 | 11q12-q13.1 | MS4A1 | membrane spanning 4-domains A1 | |
| Mouse | 4 | 291 | 19 B | Ms4a1 | membrane-spanning 4-domains | |
| Rat | - | 297 | 1q43 | Ms4a1 | membrane spanning 4-domains A1 | |
| Previous and Unofficial Names |
| B-lymphocyte antigen CD20 | MS4A2 | membrane-spanning 4-domains, subfamily A, member 1 | membrane-spanning 4-domains |
| Database Links |
|
| ChEMBL Target | CHEMBL2058 (Hs) |
| DrugBank Target | P11836 (Hs) |
| Ensembl Gene | ENSG00000156738 (Hs), ENSMUSG00000024673 (Mm), ENSRNOG00000020945 (Rn) |
| Entrez Gene | 931 (Hs), 12482 (Mm), 309217 (Rn) |
| Human Protein Atlas | ENSG00000156738 (Hs) |
| KEGG Gene | hsa:931 (Hs), mmu:12482 (Mm), rno:309217 (Rn) |
| OMIM | 112210 (Hs) |
| Orphanet | ORPHA235193 (Hs) |
| RefSeq Nucleotide | NM_152866 (Hs), NM_007641 (Mm), NM_001107578 (Rn) |
| RefSeq Protein | NP_690605 (Hs), NP_031667 (Mm), NP_001101048 (Rn) |
| UniProtKB | P11836 (Hs), P19437 (Mm) |
| Wikipedia | MS4A1 (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ofatumumab, rituximab, tositumomab and ibritumomab tiuxetan are monoclonal antibodies against the CD20 molecule (MS4A1, membrane-spanning 4-domains, subfamily A, member 1). These references contain some details of their use and function:- [3,7,10,14,16]. Although the KD value for ofatumumab is derived from [9], the originating patent is US8529902 [13]. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CD20 is a B cell antigen, involved in B cell development and maturation to antibody-producing plasma cells [4]. CD20 has no known ligand and is suggested to act as a calcium channel. CD20 is the target of monoclonal antibodies approved for the treatment of B cell lymphomas and leukemias (rituximab, obinutuzumab, Ibritumomab tiuxetan, ofatumumab and tositumomab). In obses mice, anti-CD20 antibodies prevent insulin insensitivity and development of diabetes mellitus or metabolic syndrome [15], suggesting a potentially druggable autoimmune link between obesity, diabetes mellitus and metabolic syndrome. |
| Cell Type Associations | ||||
|
| Immuno Process Associations | |||||||||
|
|||||||||
|
| Immuno Disease Associations | ||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||||
|
||||||||||||||||
References
1. Adams CW, Chan AC, Crowley CW, Lowman HB, Nakamura GR, Presta LG. (2004) Immunoglobulin variants and uses thereof. Patent number: WO2004056312. Assignee: Genentech, Inc.. Priority date: 16/12/2002. Publication date: 08/07/2004.
2. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117 (17): 4519-29. [PMID:21378274]
3. Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans., 25 (2): 705-8. [PMID:9191187]
4. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun., 8: 140-74. [PMID:15564720]
5. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest., 120 (1): 214-22. [PMID:20038800]
6. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al.. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia, 25 (1): 101-9. [PMID:20975664]
7. Leandro MJ. (2013) B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res. Ther., 15 Suppl 1: S3. [PMID:23566754]
8. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. (2017) CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy. Oncoimmunology, 7 (1): e1380142. [PMID:29296544]
9. Liu Q. (2013) Fully human antibodies against human cd20. Patent number: WO2013007052. Assignee: Qingfa Liu. Priority date: 13/07/2011. Publication date: 17/01/2013.
10. Mayes S, Brown N, Illidge TM. (2011) New antibody drug treatments for lymphoma. Expert Opin Biol Ther, 11 (5): 623-40. [PMID:21395497]
11. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2014) Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk. Lymphoma, 55 (1): 188-90. [PMID:23537278]
12. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 10 (8): 2868-78. [PMID:15102696]
13. Teeling J, Ruuls S, Glennie M, van de Winkel JGJ, Parren P, Petersen J, Baadsgaard O, Huang H. (2013) for promoting proliferation and/or differentiation of B cells involved in cancers and autoimmune disorders; animal models; genetic engineering. Patent number: US8529902. Assignee: Genmab A/S. Priority date: 17/10/2002. Publication date: 10/09/2013.
14. White CA, Berlfein JR, Grillo-López AJ. (2000) Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol, 1 (4): 303-12. [PMID:11467328]
15. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN et al.. (2011) B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med., 17 (5): 610-7. [PMID:21499269]
16. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S et al.. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 17 (12): 3793-803. [PMID:10577851]
How to cite this page
CD molecules: CD20 (membrane-spanning 4-domains, subfamily A, member 1). Last modified on 06/03/2018. Accessed on 18/02/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628.
